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Antibody responses to the full-length 
VAR2CSA and its DBL domains in Cameroonian 
children and teenagers
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and Anna Babakhanyan5
Abstract 
Background: Antigenic variation of Plasmodium falciparum erythrocyte membrane protein 1 is a key parasite mecha-
nism for immune evasion and parasite survival. It is assumed that the number of parasites expressing the same var 
gene must reach high enough numbers before the host can produce detectable levels of antibodies (Ab) to the vari-
ant. VAR2CSA is a protein coded for by one of 60 var genes that is expressed on the surface of infected erythrocytes 
(IE) and mediates IE binding to the placenta. The idea that Ab to VAR2CSA are pregnancy-associated was challenged 
when VAR2CSA-specific Ab were reported in children and men. However, the frequency and conditions under which 
Ab to VAR2CSA are produced outside pregnancy is unclear. This study sought to determine frequency, specificity and 
level of Ab to VAR2CSA produced in children and whether children with hyperparasitaemia and severe malaria are 
more likely to produce Ab to VAR2CSA compared to healthy children.
Methods: Antibody responses to a panel of recombinant proteins consisting of multiple VAR2CSA Duffy-binding-like 
domains (DBL) and full-length VAR2CSA (FV2) were characterized in 193 1–15 year old children from rural Cameroo-
nian villages and 160 children with severe malaria from the city.
Results: Low Ab levels to VAR2CSA were detected in children; however, Ab levels to FV2 in teenagers were rare. Chil-
dren preferentially recognized DBL2 (56–70%) and DBL4 (50–60%), while multigravidae produced high levels of IgG to 
DBL3, DBL5 and FV2. Sixty-seven percent of teenage girls (n = 16/24) recognized ID1–ID2a region of VAR2CSA. Chil-
dren with severe forms of malaria had significantly higher IgG to merozoite antigens (all p < 0.05), but not to VAR2CSA 
(all p > 0.05) when compared to the healthy children.
Conclusion: The study suggests that children, including teenage girls acquire Ab to VAR2CSA domains and FV2, 
but Ab levels are much lower than those needed to protect women from placental infections and repertoire of Ab 
responses to DBL domains is different from those in pregnant women. Interestingly, children with severe malaria did 
not have higher Ab levels to VAR2CSA compared to healthy children.
Keywords: Malaria, VAR2CSA, Antibody, Children
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Plasmodium falciparum remodels the host erythrocyte 
membrane upon invasion to promote parasite survival 
and immune evasion [1–5]. Plasmodium falciparum 
erythrocyte membrane protein 1 family (PfEMP1) is 
encoded by the var multigene family enable infected 
erythrocytes (IE) to become adhesive and facilitates IE 
binding to the vasculature, as an immune evasion mecha-
nism [6, 7]. Each parasite genome contains about 60 dif-
ferent var genes with high sequence diversity; however, 
at any given time, only one var gene is expressed within a 
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single IE [8], a process regulated at the level of transcrip-
tion initiation [9–11]. Placental P. falciparum parasites 
primarily express only var2csa [12–14], which appears to 
be regulated both at the transcription level and at transla-
tion initiation [15, 16]. In pregnant women, the adhesion 
ligand VAR2CSA binds to chondroitin sulfate A (CSA) 
mainly in the placental intervillous space and on syncyti-
otrophoblasts lining the intervillous space of the placenta 
[5, 12, 17, 18].
VAR2CSA is a large transmembrane protein [19] that 
is relatively conserved for the var gene family [20]. It is 
composed of six Duffy-Binding-Like domains (DBL 
domains 1–6), interspersed by inter-domain regions (ID). 
Recently, the minimal sequence of VAR2CSA required 
for binding to CSA, ID1–ID2a, which spans DBL2 was 
identified [21, 22]. As a result of IE binding to CSA, IE 
accumulate at the maternal-fetal interface causing pla-
cental malaria (PM). Pathology resulting from PM 
increases the risk of maternal anemia and poor preg-
nancy outcomes [23, 24]. In malaria endemic areas, preg-
nant women produce antibodies (Ab) to VAR2CSA over 
successive pregnancies [25] that inhibit the binding of IE 
to CSA in  vitro [26, 27], reduce maternal anaemia [28], 
and improve pregnancy outcome [25, 29, 30]. VAR2CSA-
based recombinant subunit vaccine candidates are cur-
rently under clinical evaluation [31, 32].
Ab to VAR2CSA are thought to be pregnancy specific; 
however, studies showed that they can also be detected 
in non-pregnant individuals including men and children 
[33–37]. It is assumed the number of IE expressing the 
same var gene must reach a high enough levels before 
the host can begin producing a detectable Ab response to 
each variant. Previous studies suggest that expression of 
var2csa in non-pregnant individuals results in sufficient 
exposure to the VAR2CSA to induce an Ab response [34, 
35], with biologically relevant levels confirmed by using 
the adhesion inhibition assay [33], but cross-reactive 
since they can be induced also by Plasmodium vivax [35]. 
Ab to VAR2CSA among non-pregnant individuals from 
sub-Saharan Africa are generally low [33, 34, 36], with 
exception to ID1–ID2a [36], while medium–high levels 
were observed in Colombians children and men [35]. The 
frequency and conditions under which Ab to VAR2CSA 
are produced in children and males are unclear.
Previous studies measured Ab to the surface of CSA-
binding IE [33] or to a limited number of recombinant 
VAR2CSA domains [34–36] and were either limited to 
children below 6  months [34] (who may still carry pla-
centally-transferred maternal IgG) or in undefined age 
groups [33, 35]. The current study sought to determine 
(1) when maternal IgG to VAR2CSA and its domains 
decline in neonates in the absence of exposure to var2csa 
expressing parasites, (2) whether individuals acquire 
antibodies to VAR2CSA during childhood, and (3) if chil-
dren who have hyperparasitaemia and develop severe 
malaria were more likely to produce Ab to VAR2CSA 
compared to healthy children. Young women who pro-
duced Ab to VAR2CSA as children may have an altered 
immune response upon exposure to VAR2CSA during 
pregnancy or a future placental malaria vaccine.
Methods
Ethical considerations
The use of de-identified archival samples used in the cur-
rent study was approved by the Committee on Human 
Studies, University of Hawaii, Manoa (CHS# 22332). The 
original studies were conducted according to the Helsinki 
Declaration principles and approved by the National Eth-
ics Committee, Cameroon and the Institutional Review 
Boards at the University of Hawaii and Georgetown 
University. Parents or guardians of all children provided 
written informed consent prior to inclusion of their chil-
dren into the study.
Study design
Archival plasma samples from three different studies con-
ducted in Cameroon were used. The first set of archival 
samples (COHORT 1) was from a longitudinal study con-
ducted between 2008 and 2014 in Ngali II and Ntoues-
song villages (NCT00593398), as previously described 
[38]. Pregnant women were recruited during pregnancy 
and followed monthly; they received intermittent pre-
ventive treatment with sulfadoxine-pyrimethamine and 
insecticide-treated bed nets during pregnancy. Their neo-
nates, who slept under bed nets with their mothers, were 
followed for the first year of life and plasma samples from 
cord blood, samples at 4–5 months of age (21–28 weeks) 
and 9–12 months of age (35–56 weeks) from 38 neonates 
were included in the study.
The second cross-sectional study (COHORT 2) was 
conducted between 2001 and 2003 at the Yaoundé Cen-
tral Hospital pediatric emergency unit, Cameroon [39]. 
In Yaoundé city, malaria transmission is low with about 
13 infectious bite/person/year [40, 41]. Children with 
blood smear-positive malaria (n = 160) who had uncom-
plicated malaria (n  =  41); cerebral malaria (n  =  15); 
severe malaria anaemia (n  =  35); other severe forms 
(n =  27); as well as healthy children (n =  42) all below 
five years of age were studied.
The third cohort (COHORT 3) was from a cross-sec-
tional study conducted in rural villages of Ngali II and 
Ntouessong, Cameroon, in 2012. The study was after the 
rapid scale-up of malaria intervention strategies through 
the use of insecticide-treated bed nets for vector con-
trol. This resulted in reduction of entomological inocula-
tion rate to 0.34 infectious bites/person/night; however, 
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compared to the Yaoundé city, malaria transmission was 
higher in the villages. In the 2012 study, 193 children 
aged 1–15 years old were recruited and evaluated in the 
Ngali II and Ntouessong villages. Finally, plasma from 11 
North American adults never exposed to malaria and 17 
pregnant multigravidae Cameroonian women with high 
IgG levels to VAR2CSA FCR3 strain were used as nega-
tive and positive controls, respectively.
Diagnosis of malaria and definitions
Plasmodium falciparum infections in peripheral and 
cord blood were detected by microscopy as previously 
described [40]. Uncomplicated malaria (UM) was defined 
as clinical symptoms of malaria, a positive peripheral 
blood smear parasitaemia, but with no complications. 
Cerebral malaria (CM) was defined as a Blantyre coma 
score of <3 (persisting for more than 30 min after effec-
tive treatment of hypoglycemia or seizures) in a child with 
P. falciparum parasitaemia and no other apparent cause 
of coma. Severe malaria anemia (SMA) defined according 
to WHO’s definition criteria: haemoglobin level <5.0  g/
dL (or haematocrit <15%) combined with a malaria par-
asitaemia. Others severe forms (OSF) of malaria were 
defined as complications other than the previous ones 
cited, mainly cases of seizures, prostration, hypoglycae-
mia, etc., with a positive peripheral blood smear. Healthy 
children (HC) were defined as age matched healthy chil-
dren with a negative peripheral blood smear.
Recombinant malaria proteins
Recombinant VAR2CSA DBL domains used in this 
study were described previously and include: DBL1 3D7, 
DBL1 7G8, ID1–ID2a FCR3, DBL2 FCR3, DBL3 FCR3, 
DBL3 7G8, DBL3 A4/FCR3, DBL4 FCR3, DBL4 7G8, 
DBL5 FCR3, DBL5 3D7, DBL5 7G8, DBL6 FCR3, and 
full-length VAR2CSA (FV2) FCR3 [36, 37]. Other non-
pregnancy specific antigens included were recombinant 
AMA-1 (3D7 strain) expressed in yeast provided by the 
Malaria Vaccine Development Branch (MVDB), NIH; 
recombinant EBA-175 RII expressed in yeast obtained 
from Science Applications International Corp., Freder-
ick, MD; recombinant MSP-1 42 (3D7 strain) expressed 
in Escherichia coli (MVDB); recombinant MSP-2 (FC27 
strain) (MVDB); recombinant MSP-3 C-terminal region 
expressed in E. coli provided by P. Druihle, Institute Pas-
teur, Paris, France.
Coupling of malaria proteins to magnetic beads
VAR2CSA antigens were coupled to the magnetic 
MagPlex-C microspheres using the coupling protocol 
described for SeroMap beads [36]. MSP-2 FC27 was cou-
pled at 1  µg per million beads. The rest of the protein 
concentrations for non-pregnancy specific malaria anti-
gens were described previously [42].
Measuring IgG using a multi‑analyte platform (MAP) assay
IgG to malaria antigens was measured using MAP assay 
as described before [37]. Modification includes the use 
of magnetic plate separator instead of vacuum manifold 
(Luminex, Austin, Texas, Cat# CN-0269-01) and a MAG-
PIX reader instead of Luminex 100 instrument (EMD 
Millipore, Billerica, MA). The results were expressed as 
median fluorescence intensity (MFI). Negative and posi-
tive controls were included on each plate consisting of (a) 
plasma pool of 3 North Americans who had never trav-
elled to malaria endemic areas as negative control and (b) 
pool of plasma from 7 Cameroonian multigravidae with 
high Ab levels to FV2 as positive control.
Statistical analysis
Demographic, clinical and assay variables were summa-
rized with means/medians and standard deviations (or 
interquartile ranges) for the continuous variables, and 
frequencies and percentages for categorical variables. 
Demographic and clinical parameters between three age 
groups in Table 1 were compared using Chi square trend 
test for proportions; continuous variables were com-
pared using ANOVA or Kruskal–Wallis test. Proportion 
of individuals who were seropositive for a given antigen 
was determined based on mean MFI+2 standard devia-
tion cut-off for 11 North Americans. Mann–Whitney test 
was used for all Ab level comparisons between any two 
groups of study participants. All statistical analyses were 
performed using GraphPad Prism version 6.0; p values 
less than 0.05 were regarded as statistically significant.
Results
Longevity of passively acquired antibodies to VAR2CSA 
in Cameroonian neonates
In order to follow the decline of placentally-transferred 
maternal IgG to malaria antigens, samples collected dur-
ing the first year of life (COHORT 1) from neonates liv-
ing in the Ngali II and Ntouessong villages were assessed 
(Figs.  1 and 2). The prevalence of malaria parasitaemia 
was negligeable in neonates: 1/27 in 21–28  week old 
neonates and 3/24 in 36–56  week old neonates, possi-
bly because neonates sleep under bed nets. Ab to mer-
ozoite antigens were present in all neonates (Fig.  1). 
Compared to levels at birth (cord blood), neonatal IgG 
to MSP1, MSP2 and MSP3 were significantly lower by 
21–28  weeks of age (all p values <0.05), while AMA1 
and EBA175 IgG levels were significantly reduced by 
36–56 weeks (all p values <0.05). At 36–56 week, only a 
few children had IgG to AMA1 (n = 14), EBA175 (n = 8) 
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and MSP1 (n = 8) (Fig. 1). Similarly, neonatal IgG to FV2 
and DBL domains (FCR3 strain) were present at birth in 
the majority of the neonates (FV2 n = 35, DBL2 n = 14, 
DBL3 n = 27, DBL4 n = 30, DBL5 n = 34, DBL6 n = 17) 
(Fig. 2). By 21–28 weeks of age, IgG to all DBL domains 
were significantly reduced (all p values <0.05) and were 
below cut-off levels for seropositivity, except for DBL5 
and FV2. By 36–56 weeks of age, IgG to DBL5 and FV2 
had decreased to levels similar to North American adults 
(Fig.  2). The same pattern was observed for different 
allelic variants of VAR2CSA (Additional file  1). Thus, 
overall IgG to all malarial antigens declined; when high 
IgG levels were present at birth, IgG to malaria antigens 
was detected throughout most of the first year of life, 
whereas lower levels of IgG at birth resulted in absence of 
IgG by 21–28 weeks of age.
Cameroonian children living in rural villages acquire 
antibodies against multiple VAR2CSA domains
The demographic and clinical information of children 
(COHORT 3) aged 1–5, 6–10 and 11–15 years living in 
the Ngali II/Ntouessong were summarized in Table  1. 
The proportion of children using bed nets and being 
blood smear positive were similar among the differ-
ent age groups (all p values >0.05, Table  1). The preva-
lence of malaria parasitaemia in children differed among 
the age groups, with lowest prevalence in the 1–5 age 
group (14.3%) and highest in the 6–10 age group (61%), 
p = 0.0004 (Table 1).
Based on immune responses to merozoite antigens, 
the majority of children in Ngali II and Ntouessong had 
IgG to malarial antigens, especially AMA1 (100%) and 
EBA175 (98%) (Fig.  3; Table  3). By 10  years of age, the 
majority of children in these villages had high IgG levels 
to AMA1 and EBA175 compared to younger children 
(Fig. 3). The proportion of children with Ab to VAR2CSA 
is difficult to accurately determine, since values for 
endemic male are usually used to establish the cut-off 
for Ab positivity to pregnancy-specific antigens. Using a 
cut-off based on North American adults, depending on 
the age group 56–70% children had IgG to DBL2 FCR3, 
50–60% children had IgG to DBL4 and 20–44% children 
had IgG to FV2 (Table 3). In 11–15 year old female chil-
dren, seropositivity to DBL2 FCR3 and DBL4 FCR3 was 
67 and 60% respectively (Table 3; Additional file 3), dem-
onstrating a different IgG specificity as compared to preg-
nant women, who have high IgG to DBL5 FCR3 and DBL3 
FCR3 (Fig. 4). There were no significant differences in Ab 
levels to DBL domains between groups of children who 
were seropositive for a given antigen (Fig. 4). Children had 
moderate to high-level Ab to the minimal binding region 
ID1–ID2a (Fig. 4) with 67% of 11–15 year old girls having 
Ab to ID1–ID2a (Table 3). However, high Ab to ID1–ID2a 
were not associated with higher levels of Ab to the FV2, 
suggesting that Ab to ID1–ID2a do not substantially con-
tribute to the recognition of the full-length molecule.
Since malaria prevalence was higher in 6–10  year old 
group of children, it was possible that they had higher IgG 
levels to VAR2CSA. However, IgG levels to FV2 and the 
DBL domains were similar across the three age groups. 
IgG to DBL domains from 3D7 and 7G8 strains had similar 
patterns (Additional file 2). The results show that Ab are 
Table 1 Characteristics of 193 Cameroonian children in three age groups living in the Ngali II and Ntouessong villages
* Proportions were compared using Chi square trend test, continuous variables were compared using ANOVA or Kruskal–Wallis test
a Blood smears were evaluated by microscopy for presence of P. falciparum, P. ovale, and P. malariae, Only P. falciparum was detected
b Calculated only for smear-positive individuals
c Cut-offs for anemia: children 0–5 years < 11 g/dL; 6-10 years < 11.5 g/dL; 11-15 years < 12 g/dL
1–5 years 6–10 years 11–15 years p*
Number of children 21 105 67 –
Number of male children (number, %) 10 (48%) 54 (51%) 43 (64%) 0.06
Malaria-positive by blood smears (number, percent)a 3 (14%) 64 (61%) 33 (49%) 0.0004
Malaria parasitaemia (parasites per µL, median and 25th, 75th percentile in parentheses)b 360 (360, 1320) 320 (170, 780) 360 (120, 590) 0.5
ITN use (number, %) 11 (52%) 70 (67%) 38 (57%) 0.3
Hemoglobin levels in g/dL (mean ± SD) 11 ± 2.3 11.7 ± 1.9 13 ± 1.7 <0.0001
Anemia (number, %)c 8 (38%) 47 (45%) 12 (18%) 0.001
(See figure on next page.) 
Fig. 1 Antibody levels to merozoite antigens in neonates during the first year of life. Antibody levels to 5 merozoite antigens were measured in 
neonatal samples: n = 38 cord, n = 27 samples from 21 to 28 weeks neonates, and n = 24 samples from 35 to 56 week from neonates residing in 
Ngali/Ntouessong villages. In addition, 11 North American adults and 17 Cameroonian multigravidae were included as antibody-negative and posi-
tive experimental controls. Median and interquartile ranges (IQR) are plotted, antibody levels between two groups were compared using Mann–
Whitney test. Horizontal line represents cut-off for seropositivity
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most likely cross-reactive and are targeted against domains 
other than those recognized by pregnant women.
Antibody levels to VAR2CSA domains in young children 
with severe malaria
The characteristics of children in the severe malaria cohort 
(COHORT 2) enrolled at the Yaoundé Central Hospital are 
presented in Table 2, and more detailed clinical parameters 
have been previously published [39]. The parasite load was 
highest in children with CM with median: 570,725 para-
sites/µL, IQR: 996,384 parasites/µL. Hemoglobin levels 
were lowest in SMA group (4 ± 1.7 g/dL) (Table 2). Chil-
dren with various forms of malaria had significantly higher 
levels of IgG to merozoite antigens compared to HC group; 
thus, malaria parasitaemia was associated with boosting 
of IgG to AMA-1, EBA-175, MSP-1 and MSP-2 (Fig.  5). 
It was speculated that children with hyperparasitaemia 
and CM might have parasite subpopulation express-
ing VAR2CSA and, therefore, be more likely to have IgG 
to VAR2CSA proteins. However, only IgG to DBL2 was 
significantly higher in children with CM and SMA com-
pared to HC, while IgG to the rest of VAR2CSA domains 
and FV2 were rare in children with severe malaria (Fig. 6; 
Table 3). Similar patterns were observed for the 3D7 and 
7G8 stains (Additional file 4). Thus, Ab to VAR2CSA were 
not more common in children with a high parasitaemia.
Discussion
Maternal Ab to both merozoite and VAR2CSA antigens 
were transferred to neonates, but most Ab to FV2 and the 
individual DBL domains were lost by the end of the first 
year of life. Children began producing IgG to various DBL 
domains by 1–5 years of age with only a slight non-signif-
icant increase in prevalence (Table  2) and levels (Fig.  4) 
with increasing age. Forty-four percent of teenagers had 
Ab to FV2 and levels were lower than those found in MG 
women. The specificity of Ab responses to VAR2CSA in 
children appears to be different compared to MG. Children 
recognize DBL2, DBL3 and DBL4 and to a lesser extent 
DBL5, DBL6 and FV2, while MG recognize predominantly 
DBL3, DBL5 and FV2. Children acquire moderate to high 
level antibodies against the minimal binding region in of 
VAR2CSA (ID1–ID2a) and 67% of teenage girls had Ab to 
ID1–ID2a. However, naturally acquired antibodies to ID1–
ID2a are not associated with absence of placental malaria at 
delivery [36] and do not appear to contribute substantially 
to recognition of full-length VAR2CSA ectodomain.
Neonates are born with passively transferred Ab from 
the mother during gestation. Placental transfer of anti-
bodies from mother to the fetus is an adaptive mecha-
nism by which deficiencies in neonate immunity are 
counterbalanced, providing short-term passive protec-
tion [43]. Data demonstrate that IgG to VAR2CSA DBL1, 
DBL2, DBL3, DBL4, DBL6 and ID1–ID2a are catabolized 
by 21–28 weeks of life; whereas Ab to DBL5 and the full-
length FV2, that are present at higher levels at birth, per-
sist longer with a few babies having detectable levels at 
8 months of life (35–56 weeks), decline by the end of first 
year of life. These results are in agreement with previous 
findings that the amount of Ab transferred to the neo-
nate determines the half-life [44]. In a Ghanian cohort, 
children had passively acquired Ab to P. falciparum schi-
zont extract for a median of 14 weeks [45]. In a Nigerian 
cohort of neonates, maternal Ab dropped below detect-
able levels by 4 months of age [46].
This is the first study to establish patterns of Ab acquisi-
tion to all VAR2CSA domains, ID1–ID2a and FV2 across 
three age groups of 1–15  year old children. Children in 
Ngali II and Ntouessong villages produced low levels of IgG 
to VAR2CSA domains. This is in agreement with previous 
study demonstrating that short exposure to CSA-binding 
parasites during acute illness is sufficient to induce Ab 
responses in non-pregnant individuals [33]. High malaria 
prevalence and parasitaemia in these study sites makes it 
more likely for children to be exposed to CSA-binding par-
asites and, therefore, produce Ab to VAR2CSA domains.
However, data demonstrate that 6–10 year old children 
have the highest prevalence of malaria in Ngali/Ntoues-
song rural villages, but they did not have higher IgG 
levels compared to other age groups. In addition, hyper-
parasitaemic children with CM in the city did not pro-
duce more IgG to VAR2CSA as compared to the HC. IgG 
levels to DBL1x and DBL5ɛ were previously measured in 
a cohort of young Tanzanian children (38/222 with severe 
malaria); and about 40% of 1.5–2.5 year old children rec-
ognized DBL5ɛ [34]. The differences between two studies 
could be due to different malaria transmission patterns 
between Tanzania and Cameroon, recombinant con-
structs used and definitions for cut-off for seropositivity.
Although children and young adults may have Ab to 
VAR2CSA, the specificity, magnitude, or breadth of Ab 
produced in children do not protect first-time moth-
ers from PM. Therefore, the specificity of Ab produced 
in children must be different from those produced by 
(See figure on previous page.) 
Fig. 2 Antibody levels to VAR2CSA domains in neonates during the first year of life. Antibody levels to VAR2CSA DBL domains and full-length 
protein (FV2) were measured in neonatal samples: n = 38 cord, n = 27 samples from 21 to 28 weeks neonates and n = 24 samples from 35 to 
56 week neonates residing in Ngali/Ntouessong villages In addition 11 North American adults and 17 Cameroonian multigravidae were included as 
antibody-negative and positive experimental controls. Median and interquartile ranges (IQR) are plotted, antibody levels between two groups were 
compared using Mann–Whitney test. Horizontal line represents cut-off for seropositivity
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Fig. 3 Antibody levels to merozoite antigens in children from Ngali and Ntouessong rural villages. IgG levels to five merozoite antigens were 
measured in children 0–5 years, 6–11 years and 11–15 years residing in Ngali/Ntouessong. In addition, samples from 11 adult North Americans and 
17 Cameroonian multigravidae were also measured as antibody-negative and -positive controls, respectively. Median MFI and Inter-Quartile Range 
(IQR) are plotted; dotted line shows cut-off for positivity. Antibody levels between 2 groups were compared using Mann–Whitney test. Horizontal line 
represents cut-off for seropositivity
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pregnant women with clinical protection from to placen-
tal malaria. This study is the first comparing the specificity 
of Ab to VAR2CSA between children and MG. Previous 
study by Gnidehou et al. tested children’s plasma samples 
for Ab to recombinant ID1–ID2, DBL3x and DBL5ɛ in 
Colombian non-pregnant individuals living in P. falcipa-
rum and P. vivax transmission area [35]. In this Cameroo-
nian cohort of children, specificity of IgG to VAR2CSA 
appeared to be different from that of MG, with children 
more likely responding to DBL2, DBL3 and DBL4, while 
in MG DBL5 is most immunogenic, followed by DBL3 
[36, 37, 47]. These differences in responses are important 
in the light of correlates of protection from PM. Corre-
lates of protection from PM include breadth of responses 
to multiple VAR2CSA domains, high avidity Ab to FV2 
and high levels of Ab to DBL1-2, DBL3, DBL1-3x [37, 47–
50]. In addition, it is not clear how long Ab to DBL2 and 
DBL4 persist. Although IgG to merozoite antigens and 
variant surface antigens are short lived, Ab to VAR2CSA 
DBL5ɛ are long-lived [51, 52]. Thus, young women who 
have produced Ab to VAR2CSA as children may have an 
altered immune response upon exposure to VAR2CSA 
during pregnancy or placental malaria vaccine. Pre-exist-
ing IgG to VAR2CSA could limit the efficacy of VAR2CSA 
vaccination by eliminating vaccine immunogen, as well 
as interfere with the naturally acquired immunity to 
PM. However, results from this study demonstrate that 
only a small proportion of female teenagers have IgG to 
VAR2CSA domains and full-length ectodomain. Frequent 
plasma reactivity to DBL4 in children could be explained 
by relatively conserved nature of DBL4ε (88% sequence 
homology) compared to other domains [20].
This study had several limitations, including the use 
of recombinant VAR2CSA domains and FV2, absence 
of construct control (backbone of expression vector for 
recombinant proteins), cut-off for seropositivity was dif-
ficult to define and functionality of IgG to VAR2CSA 
detected in children was not tested. Data on IgG to 
VAR2CSA from functional assays such as inhibition of 
binding to CSA in children, could help define whether 
IgG responses observed in children are to conserved 
epitopes with other PfEMP1 proteins or true responses 
to VAR2CSA. However, results from a study by Beeson 
et al., who used plasma from men and children living in 
Papua New Guinea, Kenya and Malawi in a cell surface 
binding assay using both VAR2CSA-expressing and non-
VAR2CSA expressing IE [33], showed that IgG-binding 
was specific and did not represent Ab to subpopulations 
of non-CSA-binding IE. At the same time, Gnidehou 
et  al. showed that more than 50% of Colombian men 
who had Plasmodium vivax infection recognized DBL3 
and DBL5, suggesting cross-reactive nature of these IgG. 
Thus, the role of IgG to VAR2CSA in non-pregnant indi-
viduals appear to be cross-reactive.
Table 2 Characteristics of children with severe malaria from Yaoundé city
Additional clinical characteristics for this cohort have been reported previously by Tchinda et al. [39]
a Blood smears were tested by microscopy for presence of P. falciparum, P. ovale, and P. malariae. Only P. falciparum was detected
b Cut-offs for anemia: children 0–5 years <11 g/dL
Healthy malaria 
negative (HMN)
Uncomplicated 
malaria (UM)
Cerebral malaria 
(CM)
Severe malaria  
anemia (SMA)
Others severe forms 
(OSF)
Total number of 
children
42 41 15 35 27
Average age in years 
(mean ± SD)
3.3 ± 2.2 3.3 ± 2.4 2.8 ± 1.7 1.6 ± 1.4 2.4 ± 1.8
Number males  
(percent)
20 (48%) 25 (61%) 8 (53%) 16 (46%) 12 (44%)
Malaria by blood smear 
positive (percent)a
0 100% 100% 100% 100%
Malaria parasitaemia 
(parasites per µL of 
blood, median, IQR)
– 53,225 (4098, 113,767) 570,725 (9752, 
1,158,750)
23,792 (2842, 143,213) 281,168 (98,638, 885,063)
Hemoglobin levels in 
g/dL (mean ± SD)
12 ± 2 10 ± 2 6 ± 5 4 ± 2 8 ± 3
Anemia (number, %)b 14 (33%) 37 (74%) 13 (90%) 35 (100%) 26 (97%)
(See figure on previous page.) 
Fig. 4 Antibody levels to VAR2CSA domains in children from Ngali II and Ntouessong rural villages. IgG levels to VAR2CSA DBL domains and 
full-length protein (FV2) were measured in children 0–5 years, 6–11 years and 11–15 years residing in Ngali II and Ntouessong villages. In addi-
tion, samples from 11 adult North Americans and 17 Cameroonian multigravidae were also measured as antibody-negative and -positive controls, 
respectively. Median MFI and Inter-Quartile Range (IQR) are plotted; dotted line shows cut-off for positivity
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Fig. 5 Antibody levels to merozoite antigen in children with severe malaria. IgG levels to five merozoite antigens were measured in healthy chil-
dren (HC), children with uncomplicated malaria (UM), cerebral malaria (CM), severe malaria anemia (SMA) and other severe forms of malaria (OSF). 
In addition, samples from 11 healthy adult North American adults and 17 Cameroonian multigravidae were also measured as antibody-negative 
and -positive controls, respectively. Median MFI and Inter-Quartile Range (IQR) are plotted; dotted line shows cut-off for positivity. Antibody levels 
between 2 groups were compared using Mann–Whitney test
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Fig. 6 Antibody levels to VAR2CSA domains in children with mild and severe malaria. IgG levels to VAR2CSA DBL domains and full-length protein 
(FV2) were measured in healthy children (HC), children with uncomplicated malaria (UM), children with cerebral malaria (CM), severe malaria anemia 
(SMA) and other severe forms of malaria (OSF). In addition, samples from 11 healthy adult North Americans and 17 Cameroonian multigravidae 
were also measured as antibody-negative and -positive controls, respectively. Median MFI and Inter-Quartile Range (IQR) are plotted; dotted line 
represents cut-off for seropositivity
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Interestingly, 6–15  year old children naturally acquire 
high IgG levels to ID1–ID2a, which is under clinical evalu-
ation as a vaccine against PM. However, IgG to ID1–ID2a 
are not correlated with protection in pregnant women [36] 
or with IgG to the full-length VAR2CSA ectodomain. Since 
proportion of children with IgG to ID1–ID2a was high, but 
it did not translate into high proportion of children with 
IgG to FV2 suggests that ID1–ID2a Ab acquired during 
childhood do not substantially contribute to recognition of 
the fully-folded VAR2CSA protein on the IE surface.
Conclusion
This study demonstrates induction of IgG to VAR2CSA 
domains from malaria outside pregnancy in children liv-
ing in sub-Saharan Africa. Cameroonian children, includ-
ing teenage girls acquire Ab to VAR2CSA domains and 
FV2, but Ab levels are much lower than those needed to 
protect women from placental infections and repertoire 
of Ab responses to DBL domains is different from those 
in pregnant women. Interestingly, children with severe 
malaria did not have higher Ab levels to VAR2CSA. This 
is the first report on naturally acquired Ab levels to ID1–
ID2a, a current vaccine candidate, in a small cohort of 
teenage girls living in malaria high transmission settings.
Additional files
Additional file 1. Antibody levels to merozoite antigens in neonates 
during the first year of life. Antibody levels to 5 merozoite antigens were 
measured in neonatal samples: n = 38 cord, n = 27 samples from 21 to 28 
weeks neonates, and n = 24 samples from 35 to 56 week from neonates 
residing in Ngali/Ntouessong villages. In addition, 11 North American 
adults and 17 Cameroonian multigravidae were included as antibody-
negative and -positive experimental controls. Median and interquartile 
ranges (IQR) are plotted, dotted line represents cut-off for seropositivity. 
Antibody levels between two groups were compared using Mann-
Whitney test.
Additional file 2. IgG levels to VAR2CSA domains in 10–15 year old 
Cameroonian girls living in Ngali II and Ntouessong villages. IgG levels 
to VAR2CSA DBL domains and full-length protein (FV2) were measured 
in 11–15 year old girls residing in Ngali II and Ntouessong villages. DBL1 
domain was from 3D7 strain and all the other proteins from FCR3 parasite 
strain. Median MFI and Inter-Quartile Range (IQR) are plotted.
Additional file 3. Antibody levels to VAR2CSA domains in children from 
Ngali and Ntouessong rural villages. IgG levels to VAR2CSA DBL domains 
and full-length protein (FV2) were measured in children 0-5 years, 6-11 
years and 11-15 years residing in Ngali and Ntouessong villages. In 
addition, samples from 11 adult North Americans and 17 Cameroonian 
multigravidae were also measured as antibody-negative and -positive 
controls, respectively. Median MFI and Inter-Quartile Range (IQR) are plot-
ted; dotted line shows cut-off for positivity.
Additional file 4. Antibody levels to VAR2CSA domains in children with 
mild and severe malaria. IgG levels to VAR2CSA DBL domains were meas-
ured in healthy children (HC), children with uncomplicated malaria (UM), 
children with cerebral malaria (CM), severe malaria anemia (SMA) and 
other severe forms of malaria (OSF). In addition, samples from 11 adult 
North Americans and 17 Cameroonian multigravidae were also measured 
as antibody-negative and -positive controls, respectively. Median MFI 
and Inter- Quartile Range (IQR) are plotted: dotted line shows cut-off for 
positivity.
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